Zynext Ventures USA, the venture capital arm of Zydus Lifesciences (NSE:ZYDUSLIFE, BOM:532321), has agreed to invest of an undisclosed amount in biopharmaceutical company Illexcor Therapeutics.
The investment is aimed at advancing novel oral therapy for sickle cell disease, according to a Wednesday filing to the Indian stock exchanges.
Illexcor is developing oral therapies for sickle cell disease. The lead asset, currently in preclinical development, is designed to bind to Hemoglobin S and effectively block polymerization and sickling, offering the potential for disease-modifying clinical benefits.
Zydus Lifesciences shares were up nearly 1% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。